Highlights
1 patentProfile claimed by owner
About
Targeting Drugs and Molecules into the Brain
BioPass Pharma is developing a revolutionary formulation intended for the treatment of brain or CNS diseases utilizing its patented novel technology, which is designed to deliver molecules directly into the brain by bypassing the BBB.
Its novel nasal formulation offers short onset of a non-invasive, painless, easily administered treatment, avoiding gastrointestinal and hepatic presystemic metabolism.
BioPass Pharma has secured exclusive rights for this technology from the Hebrew University of Jerusalem.
Identity
| Name | BioPass Pharma |
|---|---|
| Slug | biopass-pharma |
| Type / kind | startup |
| Source _id | v8pdqK5uwi8pzK0K5mNcEzAsAZjtD46jYzXHBmoW8rovtcT8gue7zB |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Petah Tikva |
| HQ address | Petah Tikva, Israel |
Web & social
| https://www.linkedin.com/company/94165392 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug Delivery
Technologies
Materials & SubstancesNanomaterials
Target customers
Healthcare & Life SciencesLife SciencesBiotechnologyHealthcarePatients
Business models
B2B
Tags
cns-disordersdrug-discoverytargeted-therapydrug-deliverynon-invasivepharmaceuticalsnanotechnology
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Funding |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}